Participant in Kaiser Permanente Washington Health Research Institute (KPWHRI) trial, based in Seattle, received the first injection of the SchistoShield vaccine on May 23, 2022. Participants include healthy people ages 18 through 55 years old, and assigned to different study groups based on when they enroll in the study.
The trial assess the safety of the Sm-p80 + GLA-SE (SchistoShield®) study vaccine. The research measure indicators of immunity to schistosomiasis, and whether the vaccine prompts an immune response, leading to the generation of antibodies that can prevent infection.
Please find more details of the News at: https://www.kpwashingtonresearch.org/news-and-events/recent-news/news-2022/researchers-begin-clinical-trial-assess-schistosomiasis-vaccine